Literature DB >> 26413224

Hepatitis B virus reactivation with a rituximab-containing regimen.

Yutaka Tsutsumi1, Yoshiya Yamamoto1, Shinichi Ito1, Hiroyuki Ohigashi1, Souichi Shiratori1, Hirohito Naruse1, Takanori Teshima1.   

Abstract

Rituximab is currently used not only in the treatment of B-cell lymphoma but also for various other diseases, including autoimmune diseases, post-transplant graft vs host disease, and rejection following kidney transplants. Due to rituximab's widespread use, great progress has been made regarding research into complications that arise from its use, one of the most serious being the reactivation of hepatitis B virus (HBV), and efforts continue to establish guidelines for preventive treatment against this occurrence. This report discusses preventive measures against rituximab-induced HBV reactivation and future objectives.

Entities:  

Keywords:  Hepatitis B virus; Non-Hodgkin’s lymphoma; Nucleoside analog; Reactivation; Rituximab

Year:  2015        PMID： 26413224      PMCID： PMC4577642          DOI： 10.4254/wjh.v7.i21.2344

Source DB:  PubMed          Journal:  World J Hepatol


  68 in total

1.  Chronic hepatitis B.

Authors:  Anna S F Lok; Brian J McMahon
Journal:  Hepatology       Date:  2007-02       Impact factor: 17.425

2.  Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan.

Authors:  K Kumagai; T Takagi; S Nakamura; U Sawada; Y Kura; F Kodama; S Shimano; I Kudoh; H Nakamura; K Sawada; T Ohnoshi
Journal:  Ann Oncol       Date:  1997       Impact factor: 32.976

3.  Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/ HBcAb-positive: a multicenter retrospective study.

Authors:  Dongmei Ji; Junning Cao; Xiaonan Hong; Junmin Li; Jianmin Wang; Fangyuan Chen; Chun Wang; Shanhua Zou
Journal:  Eur J Haematol       Date:  2010-05-20       Impact factor: 2.997

4.  IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma.

Authors:  D G Maloney; A J Grillo-López; D J Bodkin; C A White; T M Liles; I Royston; C Varns; J Rosenberg; R Levy
Journal:  J Clin Oncol       Date:  1997-10       Impact factor: 44.544

5.  Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP.

Authors:  Ming-Shen Dai; Tsu-Yi Chao; Woei-Yau Kao; Rong-Yaun Shyu; Tan-Mei Liu
Journal:  Ann Hematol       Date:  2004-08-25       Impact factor: 3.673

6.  Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study.

Authors:  A S Lok; R H Liang; E K Chiu; K L Wong; T K Chan; D Todd
Journal:  Gastroenterology       Date:  1991-01       Impact factor: 22.682

7.  Rituximab (anti-CD20 monoclonal antibody) as consolidation of first-line CHOP chemotherapy in patients with follicular lymphoma: a phase II study.

Authors:  Gerald Jäeger; Peter Neumeister; Ruth Brezinschek; Gerald Höfler; Franz Quehenberger; Werner Linkesch; Heinz Sill
Journal:  Eur J Haematol       Date:  2002-07       Impact factor: 2.997

8.  Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma.

Authors:  D G Maloney; T M Liles; D K Czerwinski; C Waldichuk; J Rosenberg; A Grillo-Lopez; R Levy
Journal:  Blood       Date:  1994-10-15       Impact factor: 22.113

9.  Rituximab administration and reactivation of HBV.

Authors:  Yutaka Tsutsumi; Reiki Ogasawara; Yusuke Kamihara; Shinichi Ito; Yoshiya Yamamoto; Junji Tanaka; Masahiro Asaka; Masahiro Imamura
Journal:  Hepat Res Treat       Date:  2010-12-01

10.  Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy.

Authors:  W Yeo; B Zee; S Zhong; P K S Chan; W-L Wong; W M Ho; K C Lam; P J Johnson
Journal:  Br J Cancer       Date:  2004-04-05       Impact factor: 7.640
View more
  17 in total

1.  Antigen presentation by B cells guides programing of memory CD4+ T-cell responses to a TLR4-agonist containing vaccine in mice.

Authors:  Natasha Dubois Cauwelaert; Susan L Baldwin; Mark T Orr; Anthony L Desbien; Emily Gage; Kimberly A Hofmeyer; Rhea N Coler
Journal:  Eur J Immunol       Date:  2016-11-09       Impact factor: 5.532

2.  Can rheumatoid arthritis ever cease to exist: a review of various therapeutic modalities to maintain drug-free remission?

Authors:  Di Liu; Na Yuan; Guimei Yu; Ge Song; Yan Chen
Journal:  Am J Transl Res       Date:  2017-08-15       Impact factor: 4.060

Review 3.  [Cryoglobulinemic vasculitis].

Authors:  N Blank; H-M Lorenz
Journal:  Z Rheumatol       Date:  2016-04       Impact factor: 1.372

4.  Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy.

Authors:  Shigeru Kusumoto; Luca Arcaini; Xiaonan Hong; Jie Jin; Won Seog Kim; Yok Lam Kwong; Marion G Peters; Yasuhito Tanaka; Andrew D Zelenetz; Hiroshi Kuriki; Günter Fingerle-Rowson; Tina Nielsen; Eisuke Ueda; Hanna Piper-Lepoutre; Gila Sellam; Kensei Tobinai
Journal:  Blood       Date:  2018-10-19       Impact factor: 22.113

Review 5.  Monoclonal Antibody-Based Treatments for Neuromyelitis Optica Spectrum Disorders: From Bench to Bedside.

Authors:  Wenli Zhu; Yaling Zhang; Zhen Wang; Ying Fu; Yaping Yan
Journal:  Neurosci Bull       Date:  2020-06-12       Impact factor: 5.203

6.  Borrelia miyamotoi-Associated Neuroborreliosis in Immunocompromised Person.

Authors:  Katharina Boden; Sabine Lobenstein; Beate Hermann; Gabriele Margos; Volker Fingerle
Journal:  Emerg Infect Dis       Date:  2016-09       Impact factor: 6.883

7.  Hepatitis B Serology in Patients with Rheumatic Diseases.

Authors:  Martin Feuchtenberger; Arne Schäfer; Axel Philipp Nigg; Michael Rupert Kraus
Journal:  Open Rheumatol J       Date:  2016-08-31

8.  Hurdles to the Development of Effective HBV Immunotherapies and HCV Vaccines.

Authors:  Almudena Torres-Cornejo; Georg M Lauer
Journal:  Pathog Immun       Date:  2017-04-09

9.  Occam's razor need not apply: Advanced HIV infection presenting with five simultaneous opportunistic infections and central nervous system lymphoma.

Authors:  Louis-Bassett Porter; Elena Kozakewich; Ryan Clouser; Colleen Kershaw; Andrew J Hale
Journal:  IDCases       Date:  2018-08-08

Review 10.  Immunopathology of Chronic Hepatitis B Infection: Role of Innate and Adaptive Immune Response in Disease Progression.

Authors:  Arshi Khanam; Joel V Chua; Shyam Kottilil
Journal:  Int J Mol Sci       Date:  2021-05-23       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.